DOCSLIB.ORG

United States Patent (19) 11) 4,374,829 Harris Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11) 4,374,829 Harris Et Al United States Patent (19) 11) 4,374,829 Harris et al. 45) Feb. 22, 1983 54 AMNOACD DERVATIVES AS 51 Int. Cl..................... A61K 37/00; C07C 103/52; ANTHYPERTENSIVES C07D 207/24 52 U.S. C. .............................. 424/177; 260/112.5 R 75 Inventors: Elbert E. Harris; Arthur A. Patchett, 58) Field of Search ..................... 260/326.2, 112.5 R; both of Westfield; Edward W. 424/177 Tristram, Watchung; Matthew J. Wyvratt, Mountainside, all of N.J. (56) References Cited PUBLICATIONS (73) Assignee: Merck & Co., Inc., Rahway, N.J. Theohanson, et al., J. Biol. Chem. 175, (1948) 833–848. 21 Appl. No.: 235,335 Primary Examiner-Delbert R. Phillips Attorney, Agent, or Firm-Salvatore C. Mitri; Martin L. (22) Filed: Feb. 17, 1981 Katz Related U.S. Application Data (57) ABSTRACT 63 Continuation-in-part of Ser. No. 79,898, Oct. 9, 1979, The invention relates to new carboxyalkyl dipeptide abandoned, which is a continuation-in-part of Ser, No. derivatives and related compounds which are useful as 36,279, May 7, 1979, abandoned, which is a continua antihypertensives. tion-in-part of Ser. No. 968,249, Dec. 11, 1978, aban doned. 82 Claims, No Drawings 4,374,829 2 R and R6 are the same or different and are hydroxy, AMNOACD DERVATIVES AS lower alkoxy, ANTHYPERTENSIVES lower alkenoxy, dillower alkylamino lower alkoxy (dimethylaminoe RELATED APPLICATIONS thoxy), This application is a continuation-in-part of U.S. Ser. acylamino lower alkoxy (acetylaminoethoxy), No. 079,898 filed Oct. 9, 1979 which is a continuation acyloxy lower alkoxy (pivaloyloxymethoxy), in-part of U.S. Ser. No. 036,279 filed May 7, 1979, both aryloxy, such as phenoxy, now abandoned, which is a continuation-in-part of U.S. arloweralkoxy, such as benzyloxy, 10 substituted aryloxy or substituted arloweralkoxy Ser. No. 968,249 filed Dec. 11, 1978, now abandoned. wherein the substitutent is methyl, halo or me BACKGROUND OF THE INVENTION thoxy, U.S. Pat. Nos. 4,129,571 and 4,154,960 disclose substi amino, tuted acyl derivatives of amino acids which are useful as loweralkylamino, angiotension converting enzyme inhibitors. More spe 15 diloweralkylamino, cifically, these compounds are mercapto substituted hydroxyamino, acyl amino acids and derivatives thereof including the arloweralkylamino such as benzylamino; clinically effective antihypertensive compound, capto R is hydrogen, pril, i.e., D-3-mercapto-2-methylpropanoyl-L-proline. alkyl of from 1 to 20 carbon atoms which include 20 branched and cyclic and unsaturated (such as allyl) The foregoing prior art compounds are not dipeptide alkyl groups, derivatives as are the compounds of the present inven substituted loweralkyl wherein the substituent can be tion. Furthermore, these prior art compounds contain halo, hydroxy, lower alkoxy, aryloxy such as phe an essential sulfhydryl substituent or derivative thereof noxy, amino, dilloweralkylamino, acylamino, such whereas those of the present invention do not. In addi 25 as acetamido and benzamido, arylamino, tion, the dipeptide compounds of the present invention guanidino, imidazolyl, indolyl, mercapto, loweral are unusual dipeptides whose N-terminus bears a car kylthio, arylthio such as phenlithio, carboxy or boxymethyl group which is preferably further substi carboxamido, carboloweralkoxy, tuted on the methyl group. In addition, the carboxyl aryl such as phenyl or naphthyl, group(s) may also be converted to ester, amide and salt 30 substituted aryl such as phenyl wherein the substitu derivatives. In effect, the compounds of the present ent is lower alkyl, lower alkoxy or halo, invention are hybrids formed by fusing a-amino acids arloweralkyl, arloweralkenyl, heteroarlower alkyl or onto dipeptides by means of a nitrogen shared by these heteroarlower alkenyl such as benzyl, styryl or two part-structures. This structural arrangement is rare indolyl ethyl, in the field of synthetic and natural peptides and is not 35 substituted arloweralkyl, substituted arloweralkenyl, suggested or disclosed by the mercaptoacyl type func substituted heteroarlower alkyl, or substituted tions of the two prior art patents identified above. heteroarlower alkenyl, wherein the substituent(s) is U.S. Pat. No. 4,052,511 discloses N-carboxyalkanoyl halo, dihalo, lower alkyl, hydroxy, lower alkoxy, amino acids which are useful as angiotension converting amino, aminomethyl, acylamino (acetylamino or enzyme inhibitors. Since the compounds of the present benzoylamino) dilloweralkylamino, loweralk invention are dipeptide derivatives, in a formal sense ylamino, carboxyl, haloloweralkyl, cyano or sul they may be considered to be related to some of the fonamido; compounds disclosed in U.S. Pat. No. 4,052,511. How arloweralkyl or heteroarloweralkyl substituted on ever, when a particular one of the methylene groups is the alkyl portion by amino or acylamino replaced by an amino function as in the present inven 45 (acetylamino or benzoylamino); tion, compounds of surprisingly high potency are ob R2 and R7 are the same or different and are hydrogen or tained. For example, the preferred compounds of the lower alkyl; present invention can be administered in dosages as low R3 is hydrogen, lower alkyl, phenyl lower alkyl, amino as about 2.5 mg. per patient per day as opposed to the methyl phenyl lower alkyl, hydroxy phenyl lower lowest dosage level of 1 mg. per kg. per day for pre 50 alkyl, hydroxy lower alkyl, acylamino lower alkyl ferred compounds disclosed in the U.S. Pat. No. (such as benzoylamino lower alkyl, acetylamino 4,052,511 patent which is about equivalent to 60 mg. per lower alkyl), amino lower alkyl, dimethylamino patient per day based on an average patient weight of lower alkyl, halo lower alkyl, guanidino lower alkyl, about 150 pounds. imidazolyl lower alkyl, indolyl lower alkyl, mercapto 55 lower alkyl, lower alkyl thio lower alkyl; SUMMARY OF THE INVENTION R is hydrogen or lower alkyl; The invention in its broad aspects relates to carboxy Rishydrogen, lower alkyl, phenyl, phenyl lower alkyl, alkyl dipeptides and derivatives thereof which are use hydroxy phenyl lower alkyl, hydroxy lower alkyl, ful as converting enzyme inhibitors and as antihyperten amino lower alkyl, guanidino lower alkyl, imidazolyl sives. The compounds of this invention can be shown by 60 lower alkyl, indolyl lower alkyl, mercapto lower the following formula: alkyl or lower alkyl thio lower alkyl; R“and R5 may be connected together to form an alkyl O R1 R3 R R5 O. ene bridge of from 2 to 4 carbon atoms, an alkylene II R-C-C-NH-CH-C-N-C-C-R6 bridge of from 2 to 3 carbon atoms and one sulfur 65 atom, an alkylene bridge of from 3 to 4 carbon atoms R2 O R7 containing a double bond or an alkylene bridge as above substituted with hydroxy, loweralkoxy, lower wherein alkyl or diloweralkyl; 4,374,829 3 4. and the pharmaceutically acceptable salts thereof. stituent(s) is halo, dihalo, amino, aminoalkyl, hy The loweralkyl or lower alkenyl groups except droxy, lower alkoxy or lower alkyl. Most preferred where noted otherwise represented by any of the vari ables include straight and branched chain hydrocarbon are compounds of Formula I wherein radicals from one to six carbon atoms, for example, R and R6 are hydroxy, lower alkoxy, aralkyloxy; methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, R2 and R7 are hydrogen; pentyl, isopentyl, hexyl or vinyl, ally, butenyl and the R3 is methyl or amino lower alkyl; like. The aralkyl groups represented by any of the R and Rare joined through the carbon and nitrogen above variables have from one to four carbon atoms in atom to form proline, 4-thiaproline or 4-methoxy the alkyl portion thereof and include for example, ben 10 proline; zyl, p-methoxybenzyl and the like. Halo means chloro, bromo, iodo or fluoro. Aryl where it appears in any of R is alkyl having from 1 to 8 carbon atoms, substituted the radicals except where noted represents phenyl or lower alkyl wherein the alkyl group has 1-5 carbon naphthyl. Heteroaryl groups where they appear include atoms and the substituent is amino, arylthio or aryl for example pyridyl, thienyl, furyl, indolyl, benzthienyl, 15 oxy, aralkyl or heteroaralkyl wherein the alkyl por imidazoyl and thiazolyl. tion has 1 to 3 carbon atoms such as phenethyl or The R1, R3 and R5 substituted lower alkyl moieties indolylethyl or substituted aralkyl (phenyl lower are exemplified by groups such as alkyl or naphthyl lower alkyl) and substituted heteroaralkyl wherein the alkyl groups have 1-3 car 20 bons and wherein the substituent(s) is halo, dihalo, N CH2 CH2 amino, aminoalkyl, hydroxy, lower alkoxy or lower CH2 alkyl. N N The preferred, more preferred and most preferred H H 25 compounds also include the pharmaceutically accept able salts thereof and are exemplified by such com pounds as: N-(1(S)-carboxy-3-phenylpropyl)-L-alanyl-L-proline; NH N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L- H2N-C-NH-(CH2)3- and the like. 30 proline and its maleate salt; N-(1(S)-ethoxycarbonyl-4-methylpentyl)-L-alanyl-L- Rand R5 when joined through the carbon and nitro proline; gen atoms to which they are attached form a 4 to 6 N-(1-carboxy-5-aminopentyl)-L-alanyl-L-proline; membered ring which may contain one sulfur atom or a 35 N-a-(1(S)-carboxy-3-phenylpropyl)-L-lysyl-L-proline; double bond. Preferred rings have the formulae: N-a(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-lysyl-L- proline; N-a1(S)-carboxy-3-(3-indolyl)propyl)-L-lysyl-L-pro -N OR -N line; N-a-1(S)-carboxy-3-(4-chlorophenyl)-propyl)-L-lysyl L-proline; COOR N-a-1 (S)-carboxy-2-phenylthioethyl)-L-lysyl-L-pro where Y is CH2, S, or CHOCH3. line; Preferred are those compounds of Formula I 45 N-a-1 (S)-carboxy-3-(4-chlorophenyl)-propyl-L-lysyl wherein: L-4-a-methoxyproline; R and R can each independently by hydroxy, lower N-a-1(S)-carboxy-5-aminopentyl-L-lysyl-L-proline; alkoxy, lower alkenoxy, arloweralkyloxy, amino, Ethyl N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-ala dillower alkylamino lower alkoxy, acylamino lower nyl-L-prolinate hydrochloride; alkoxy, acyloxy lower alkoxy wherein the substituent 50 is methyl, halo or methoxy; and the like.
Load more

Recommended publications
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Questions in the Chemical Enzymology of MAO
    Review Questions in the Chemical Enzymology of MAO Rona R. Ramsay 1,* and Alen Albreht 2 1 Biomedical Sciences Research Complex, School of Biology, University of St Andrews, St Andrews KY16 9ST, UK 2 Laboratory for Food Chemistry, Department of Analytical Chemistry, National Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia; [email protected] * Correspondence: [email protected]; Tel.: +44-(0)-1334-474740 Abstract: We have structure, a wealth of kinetic data, thousands of chemical ligands and clinical information for the effects of a range of drugs on monoamine oxidase activity in vivo. We have comparative information from various species and mutations on kinetics and effects of inhibition. Nevertheless, there are what seem like simple questions still to be answered. This article presents a brief summary of existing experimental evidence the background and poses questions that remain intriguing for chemists and biochemists researching the chemical enzymology of and drug design for monoamine oxidases (FAD-containing EC 4.1.3.4). Keywords: chemical mechanism; kinetic mechanism; oxidation; protein flexibility; cysteine modifica- tion; reversible/irreversible inhibition; molecular dynamics; simulation 1. Introduction Monoamine oxidase (E.C. 1.4.3.4) enzymes MAO A and MAO B are FAD-containing Citation: Ramsay, R.R.; Albreht, A. proteins located on the outer face of the mitochondrial inner membrane, retained there Questions in the Chemical Enzymology of MAO. Chemistry 2021, by hydrophobic interactions and a transmembrane helix. The redox co-factor (FAD) is 3, 959–978. https://doi.org/10.3390/ covalently attached to a cysteine and buried deep inside the protein [1].
    [Show full text]
  • Azilect, INN-Rasagiline
    SCIENTIFIC DISCUSSION 1. Introduction AZILECT is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. Rasagiline is administered orally, at a dose of 1 mg once daily with or without levodopa. Parkinson’s disease is a common neurodegenerative disorder typified by loss of dopaminergic neurones from the basal ganglia, and by a characteristic clinical syndrome with cardinal physical signs of resting tremor, bradikinesia and rigidity. The main treatment aims at alleviating symptoms through a balance of anti-cholinergic and dopaminergic drugs. Parkinson’s disease (PD) treatment is complex due to the progressive nature of the disease, and the array of motor and non-motor features combined with early and late side effects associated with therapeutic interventions. Rasagiline is a chemical inhibitor of the enzyme monoamine oxidase (MAO) type B which has a major role in the inactivation of biogenic and diet-derived amines in the central nervous system. MAO has two isozymes (types A and B) and type B is responsible for metabolising dopamine in the central nervous system; as dopamine deficiency is the main contributing factor to the clinical manifestations of Parkinson’s disease, inhibition of MAO-B should tend to restore dopamine levels towards normal values and this improve the condition. Rasagiline was developed for the symptomatic treatment of Parkinson’s disease both as monotherapy in early disease and as adjunct therapy to levodopa + aminoacids decarboxylase inhibitor (LD + ADI) in patients with motor fluctuations. 2. Quality Introduction Drug Substance • Composition AZILECT contains rasagiline mesylate as the active substance.
    [Show full text]
  • Evidence That Formulations of the Selective MAO-B Inhibitor, Selegiline, Which Bypass First-Pass Metabolism, Also Inhibit MAO-A in the Human Brain
    Neuropsychopharmacology (2015) 40, 650–657 OPEN & 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain Joanna S Fowler*,1, Jean Logan2, Nora D Volkow3,4, Elena Shumay4, Fred McCall-Perez5, Millard Jayne4, Gene-Jack Wang4, David L Alexoff1, Karen Apelskog-Torres4, Barbara Hubbard1, Pauline Carter1, 1 6 7 4 1 1 4 Payton King , Stanley Fahn , Michelle Gilmor , Frank Telang , Colleen Shea , Youwen Xu and Lisa Muench 1Biological, Environmental and Climate Sciences Department, Brookhaven National Laboratory, Upton, NY, USA; 2New York University Langone Medical Center, Department of Radiology, New York, NY, USA; 3National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, 4 5 USA; National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA; Targeted Medical Pharma Inc, 6 7 Los Angeles, CA, USA; Department of Neurology, Columbia University Medical Center, New York, NY, USA; Novartis Pharmaceuticals, East Hanover, NJ, USA Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson’s disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline and for transdermal selegiline suggesting that when plasma levels of selegiline are elevated, brain MAO-A might also be inhibited. Zydis selegiline (Zelapar) is an orally disintegrating formulation of selegiline, which is absorbed through the buccal mucosa producing higher plasma levels of selegiline and reduced amphetamine metabolites compared with equal doses of conventional selegiline.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived Streptomyces Sp. CNQ-027
    J. Microbiol. Biotechnol. (2017), 27(4), 785–790 https://doi.org/10.4014/jmb.1612.12025 Research Article Review jmb Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived Streptomyces sp. CNQ-027 Hyun Woo Lee1, Hansol Choi2, Sang-Jip Nam2, William Fenical3, and Hoon Kim1* 1Department of Pharmacy and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea 2Department of Chemistry and Nano Science, Ewha Womans University, Seoul 03760, Republic of Korea 3Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, La Jolla, CA 92093-0204, USA Received: December 19, 2016 Revised: December 27, 2016 Two piloquinone derivatives isolated from Streptomyces sp. CNQ-027 were tested for the Accepted: January 4, 2017 inhibitory activities of two isoforms of monoamine oxidase (MAO), which catalyzes monoamine neurotransmitters. The piloquinone 4,7-dihydroxy-3-methyl-2-(4-methyl-1- oxopentyl)-6H-dibenzo[b,d]pyran-6-one (1) was found to be a highly potent inhibitor of First published online human MAO-B, with an IC50 value of 1.21 µM; in addition, it was found to be highly effective January 9, 2017 against MAO-A, with an IC50 value of 6.47 µM. Compound 1 was selective, but not extremely *Corresponding author so, for MAO-B compared with MAO-A, with a selectivity index value of 5.35. Compound 1,8- Phone: +82-61-750-3751; dihydroxy-2-methyl-3-(4-methyl-1-oxopentyl)-9,10-phenanthrenedione (2) was moderately Fax: +82-61-750-3708; effective for the inhibition of MAO-B (IC = 14.50 µM) but not for MAO-A (IC > 80 µM).
    [Show full text]
  • Some Pharmacological Properties of Trimethoxy Analogs of Pheniramine, Tripelennamine, and Diphenhydramine
    University of Rhode Island DigitalCommons@URI Open Access Master's Theses 1966 Some Pharmacological Properties of Trimethoxy Analogs of Pheniramine, Tripelennamine, and Diphenhydramine Ronald Otto Langner University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/theses Recommended Citation Langner, Ronald Otto, "Some Pharmacological Properties of Trimethoxy Analogs of Pheniramine, Tripelennamine, and Diphenhydramine" (1966). Open Access Master's Theses. Paper 200. https://digitalcommons.uri.edu/theses/200 This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. SOME PHARMACOLOGICAL PRDPERTIES OF TRIMETHOXY ANALOGS OF PHENIRAMINE,_ TRIPELENNAMINE, AND DIPHENHYDRAMINE BY RONALD OT'ID LANGNER A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FDR THE DEGREE OF MASTER OF SCIENCE IN PHARMACOLOGY UNIVERSITY OF RHODE ISLAND 1966 ABSTRACT Trimethoxy analogs of tripelennamine, diphenhydramine, and pheniramine were studied to determine the influences of the tri­ methoxy group on the pharmacological activity of known antihista­ mines. In this investigation, the ability of the parent compounds and their analogs to antagonize the histamine-induced contractions of guinea pig ilia were studied as well as their effects on the systolic blood pressure of male albino rats and on the central nervous system of mice as measured by the actophotometer. 'lhe trimethoxy analogs were comparatively weak competitive antagonists of histamine with the exception of N,N,-Diethyl-N'­ (2-pyridyl)-N'-(3,4,S-trimethoxybenzyl) ethylenediamine Dicyclamate (De-TMPBZ) and N,N,-Diethyl-N'-(2-pyridyl)-N'-(3,4,5-trimethoxy­ benzyl) ethylenediamine Disuccinate (TMPBZ) which were weak non­ competitive histamine antagonists.
    [Show full text]
  • Pharmacological Aspects of the Neuroprotective Effects Of
    Journal of Neural Transmission https://doi.org/10.1007/s00702-018-1853-9 NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES - REVIEW ARTICLE Pharmacological aspects of the neuroprotective efects of irreversible MAO‑B inhibitors, selegiline and rasagiline, in Parkinson’s disease Éva Szökő1 · Tamás Tábi1 · Peter Riederer2 · László Vécsei3,4 · Kálmán Magyar1 Received: 4 January 2018 / Accepted: 31 January 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 Abstract The era of MAO-B inhibitors dates back more than 50 years. It began with Kálmán Magyar’s outstanding discovery of the selective inhibitor, selegiline. This compound is still regarded as the gold standard of MAO-B inhibition, although newer drugs have also been introduced to the feld. It was revealed early on that selective, even irreversible inhibition of MAO-B is free from the severe side efect of the non-selective MAO inhibitors, the potentiation of tyramine, resulting in the so-called ‘cheese efect’. Since MAO-B is involved mainly in the degradation of dopamine, the inhibitors lack any antidepressant efect; however, they became frst-line medications for the therapy of Parkinson’s disease based on their dopamine-sparing activity. Extensive studies with selegiline indicated its complex pharmacological activity profle with MAO-B-independent mechanisms involved. Some of these benefcial efects, such as neuroprotective and antiapoptotic properties, were connected to its propargylamine structure. The second MAO-B inhibitor approved for the treatment of Parkinson’s disease, rasagiline also possesses this structural element and shows similar pharmacological characteristics. The preclinical studies performed with selegiline and rasagiline are summarized in this review. Keywords MAO-B inhibition · Selegiline · Rasagiline · Neuroprotection Introduction inhibitor in the 1960s (Knoll et al.
    [Show full text]
  • Application Number
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207145Orig1s000 PHARMACOLOGY REVIEW(S) Tertiary Pharmacology Review By: Paul C. Brown, Ph.D., ODE Associate Director for Pharmacology and Toxicology, OND IO NDA: 207145 Submission date: 5/29/2014 Drug: Safinamide Applicant: Newron Pharmaceuticals Indication: adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes Reviewing Division: Division of Neurology Products Discussion: The primary reviewer and supervisor found the nonclinical information adequate to support the approval of safinamide for the indication listed above. Safinamide is an inhibitor of monoamine oxidase B. Although the exact mechanism by which safinamide exerts it therapeutic effect is not known, increased dopaminergic activity in the brain induced by inhibition of monoamine oxidase B is thought to be beneficial in Parkinson’s disease. The Established Pharmacologic Class of Monoamine Oxidase Type B Inhibitor is appropriate for safinamide. The carcinogenicity of safinamide was assessed in 2-year rat and mouse studies. These studies were found to be acceptable by the executive carcinogenicity assessment committee and the committee concluded that there were no drug- related neoplasms in either species. Retinal toxicity and cataracts were observed in rats treated with safinamide. These effects occurred at exposures below those achieved in humans at the maximum recommended dose. The relevance to humans is unknown but cannot be excluded. Proposed labeling includes warning about this possible toxicity. Safinamide alone and in combination with levodopa and carbidopa produced adverse developmental effects in animals at doses similar to those used in humans. Proposed labeling includes description of these findings. Conclusions: I agree that this NDA can be approved from a pharm/tox perspective for the indication listed above.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Monoamine Oxidase Inhibition Causes a Long-Term Prolongation of the Dopamine-Induced Responses in Rat Midbrain Dopaminergic Cells
    The Journal of Neuroscience, April 1, 1997, 17(7):2267–2272 Monoamine Oxidase Inhibition Causes a Long-Term Prolongation of the Dopamine-Induced Responses in Rat Midbrain Dopaminergic Cells Nicola B. Mercuri, Mariangela Scarponi, Antonello Bonci, Antonio Siniscalchi, and Giorgio Bernardi Clinica Neurologica, Dipartimento Sanita´ Pubblica, Universita´ di Roma Tor Vergata and Istituto Ricerca e Cura a Carattere Scientifico Ospedale Santa Lucia, Roma, Italy The way monoamine oxidase (MAO) modulates the depression over, the effects of DA were not largely prolonged during the of the firing rate and the hyperpolarization of the membrane simultaneous inhibition of MAO and the DA reuptake system. caused by dopamine (DA) on rat midbrain dopaminergic cells Interestingly, the actions of amphetamine were not clearly aug- was investigated by means of intracellular recordings in vitro. mented by MAO inhibition. The cellular responses to DA, attributable to the activation of From the present data it is concluded that the termination of somatodendritic D2/3 autoreceptors, were prolonged and did DA action in the brain is controlled mainly by MAO enzymes. not completely wash out after pharmacological blockade of This long-term prolongation of the dopaminergic responses both types (A and B) of MAO. On the contrary, depression of the suggests a substitutive therapeutic approach that uses MAO firing rate and membrane hyperpolarization induced by quinpi- inhibitors and DA precursors in DA-deficient disorders in which role (a direct D2 receptor agonist) were not affected by MAO continuous stimulation of the dopaminergic receptors is inhibition. Furthermore, although the inhibition of DA reuptake preferable. by cocaine and nomifensine caused a short-term prolongation of DA responses, the combined inhibition of MAO A and B Key words: pargyline; cocaine; nomifensine; intracellular re- enzymes caused a long-term prolongation of DA effects.
    [Show full text]
  • ANTIHISTAMINES Antihistamines Need to Be Stopped 7 Days Prior to Allergy Testing
    ANTIHISTAMINES Antihistamines need to be stopped 7 days prior to allergy testing Actifed Cetirizine Extendryl Rutuss Advil Allergy Chlorphenirmine Fexofenadine Ryna Advil PM Clortrimeton Hydroxyzine Rynatan Alavert Clarinex Hyzine Ryneze Allegra Claritin Lodrane Semprex Allerhist Clemastine Loratadine Singlet Allertan Cogentin Nyquil Sominex Allerx Comtrex Omnaris nasal spray Astelin nasal spray Contac Optivar eye drops Tandur Astepro nasal spray Coricidin Pataday Travist Atarax Cyproheptadine Patanase nasal spray Temaril Atrohist Deconamine Patanol eye drops Theraflu BC Cold Dimetapp PediaCare Triaminic Benadryl Diphenhydramine Pediatan Trinalin Bentyl Dramamine Periactin Tylenol (any but plain) Benztropin Drixoral Polyhistine Unisom Biohist Durahist Pyribenzamine Vicks Bonine Duratan Rescon Vistacot Bromfed Duravent Restall Vistaril IM Brompheniramine Dytan Robitussin Xyzal Carbinoxamine Excedrin PM Rondec Zyrtec ANTI-INFLAMMATORY Anti-inflammatory medications must be stopped 7 days prior to allergy testing Aspirin Celebrex Motrin Aleve Naprosyn (Naproxen) Flexeril Advil Excedrin (PM & Cold/Sinus) Ibuprofen Alka-Seltzer Prednisone Vioxx Meloxicam cold medications BETA BLOCKERS Beta blocker drugs need to be stopped 7 days prior to allergy testing. DO NOT STOP WITHOUT PRESCRIBING PROVIDERS AUTHORIZATION! ORAL COMBINATION PRODUCTS Brand Name Generic Name Brand Name Generic Name Apo-Metoprolol metoprolol Cobetaloc metroprolol/HCTZ Apo-Propranolol propranolol Corzide Nadolol Betaloc metoprolol Inderide propranolol/HCTZ Betapace/AF sotalol
    [Show full text]